Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Memory T cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Memory T cells. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-004310-33 Sponsor Protocol Number: CAR4SAR Start Date*: 2022-02-21
    Sponsor Name:Dr. Antonio Pérez Martínez
    Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma
    Medical condition: Advanced Sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022066-28 Sponsor Protocol Number: CFTY720DDE01 Start Date*: 2011-01-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple ...
    Medical condition: relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002378-37 Sponsor Protocol Number: LIS/IMM138 Start Date*: 2008-12-23
    Sponsor Name:National Institute of Health and the Environment (RIVM)
    Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination.
    Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001864-50 Sponsor Protocol Number: IIV-268 Start Date*: 2013-07-22
    Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands)
    Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc...
    Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007235-40 Sponsor Protocol Number: 2008-007235 Start Date*: 2009-06-10
    Sponsor Name:Department für Pädiatrie, Medizinische Universität Innsbruck
    Full Title: Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors
    Medical condition: Patients (aged 24 months to 80 years) listed for renal transplantation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000937-15 Sponsor Protocol Number: HO161 Start Date*: 2022-08-25
    Sponsor Name:UMCG
    Full Title: A phase II non-inferiority design study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
    Medical condition: B-Cell Non Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004747-23 Sponsor Protocol Number: BPC01-001 Start Date*: 2014-01-17
    Sponsor Name:Bionor Pharma ASA
    Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic...
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001927-74 Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) Start Date*: 2009-01-16
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES...
    Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001304-15 Sponsor Protocol Number: AZGS2021005 Start Date*: 2021-05-06
    Sponsor Name:vzw az groeninge
    Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-...
    Medical condition: immuneresponse after vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002530-14 Sponsor Protocol Number: SI101-02 Start Date*: 2023-03-10
    Sponsor Name:SMART IMMUNE
    Full Title: An open-label, multi-center phase I/II study to assess the safety and the efficacy of SMART101 after -haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide in s...
    Medical condition: Patients with hematological malignancies requiring haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004073-27 Sponsor Protocol Number: 18082A0002 Start Date*: 2019-03-13
    Sponsor Name:ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC)
    Full Title: Dupilumab impact on skin resident memory T cells
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000307-20 Sponsor Protocol Number: COMB157GDE01 Start Date*: 2021-04-28
    Sponsor Name:Novartis Pharma Vertriebs GmbH
    Full Title: Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001522-41 Sponsor Protocol Number: PACT2014-001 Start Date*: 2016-02-08
    Sponsor Name:University Hospital Wuerzburg
    Full Title: Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications
    Medical condition: patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after T cell depleted allo-SCT
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028555 Myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000836-24 Sponsor Protocol Number: IIV-406 Start Date*: 2019-06-19
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults.
    Medical condition: Healthy volunteers above 25 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005984-29 Sponsor Protocol Number: NL76248.091.20 Start Date*: 2021-06-28
    Sponsor Name:Radboud University Medical Center
    Full Title: [89Zr]Df-IAB22M2C anti-CD8 minibody PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in COVID-19 patients
    Medical condition: Proven COVID-19.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001080-27 Sponsor Protocol Number: CD45RADLIHaplo Start Date*: 2022-11-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic...
    Medical condition: Patients suffering from hematological malignancies and eligible for haploidentical allogeneic stem cell transplantation. Patients will be included prior start of conditioning for SCT. Inclusion cri...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2015-001327-23 Sponsor Protocol Number: ITP0815 Start Date*: 2015-06-26
    Sponsor Name:Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and ...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000417-16 Sponsor Protocol Number: Uni-Köln-4480 Start Date*: 2021-10-20
    Sponsor Name:University of Cologne
    Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19
    Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004445-17 Sponsor Protocol Number: hCMV2013 Start Date*: 2014-03-05
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS
    Medical condition: cytomegalovirus infection in renal tranplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:57:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA